Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival

Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival

Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy. However, acquiring resistance to ven...

Full description

Bibliographic Details
Main Authors: Hind A. Alkhatabi, Samir F. Zohny, Mohammed Razeeth Shait Mohammed, Hani Choudhry, Mohd Rehan, Aamir Ahmad, Farid Ahmed, Mohammad Imran Khan
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Antioxidants
Subjects:
venetoclax
acute myeloid leukemia
MV4-11
venetoclax resistance model
metabolomics
PI3K/AKT pathway
Online Access:https://www.mdpi.com/2076-3921/11/3/461

Internet

https://www.mdpi.com/2076-3921/11/3/461

Similar Items